Oct. 5 at 2:03 PM
$EDSA Sentiment is a real thing and it impacts price, full stop. What this company doesn't have is a story. Most bios have an easily surmisable 2-4 sentence bull or bear thesis that can easily be understood by any peon. They've failed miserably in that branding exercise. In my view, barring any out of left field positive / negative catalyst(s), 2026 will continue to remain a "transition year". JB max trial site activation should happen at the one year mark and the Vitiligo trial should be underway by next summer. 2027 is when things should start to meaningfully heat up. My two year PT remains unchanged at
$8....EVEN with the continued headwinds.
